The effect of hepatic steatosis on 18F-FDG uptake in PET-CT examinations of cancer Egyptian patients

Abstract

Background Hepatic steatosis is the most common chronic hepatic disease. Imaging diagnosis of hepatic steatosis has been evaluated as an alternative to invasive histological diagnosis. Study aims The study aimed to assess the effect of hepatic steatosis on Flourine-18 fluorodeoxyglucose (18F-FDG) uptakes in cancer patients. Patients and Methods Blood samples were collected from 50 cancer patients and analyzed to calculate fatty liver index and Hepatic steatosis index (HIS). Hepatic steatosis examined using high-resolution ultrasound and positron emission tomography—computed tomography (PET-CT). Linear attenuation coefficient, standardized-uptake value (SUV) mean (SUV mean), and SUV maximum (SUVmax) were measured. Accordingly, patients were divided equally into non-fatty liver, and fatty liver groups. Results A significant increase in SUVmax and SUV mean was observed in the fatty liver group more than in the non-fatty liver group. HSI significantly increased in the fatty liver group compared to the non-fatty liver group. Liver tissue uptake FDG was significantly correlated with HSI values. SUV max significantly correlated with body mass index (BMI) in the non-fatty group only. Conclusion Hepatic changes in cancer patients affect the liver metabolic activity and thus the 18 F-FDG uptake. Therefore, further corrections should be considered when the liver is used as a comparator for PET-CT scans of cancer patients.

Non-invasive PET imaging of liver fibrogenesis using a RESCA-conjugated Affibody molecule

“…However, the inherent lack of specificity in [ 18 F]FDG, which primarily reflects glucose use, poses challenges due to potential influences from factors unrelated to fibrogenesis. [ 18 F]FDG uptake was observed in both the steatosis 10 , 11 and fibrosis 12 stages, indicating that its uptake does not appear to be specific to fibrosis. To address these limitations, our approach involves imaging a receptor that is selectively expressed on the surface of fibrogenic cells to achieve a more precise and specific assessment of fibrogenesis.…”

Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease—Clinical and Pre-Clinical Overview and Systematic Review of the Literature

“…Regarding Positron Emission Tomography-Computed tomography scan (PET/CT) usefulness in staging and diagnosing NAFLD, there are needed standards because the relationship between body mass index and correction of standardized uptake value (SUV) of [18F]2-fluoro-2-deoxy-D-glucose (18F-FDG) dosage is not established in non-malignant cases [35,36]. Alternative PET/CT tracers proposed for liver steatosis diagnosing are 14 (R, S)-[18F] fluoro-6-thia-Heptadecanoic acid (18F-FTHA), 11C-Palmitate, and 11C-Acetate, but still need validation and standardization [37].…”